The cancer diagnostics company is hours away from losing funding for its tests through the US Medicare system.
Gentailer sees significant upside from Manawa acquisition when its supply contract with Mercury resets to market price.
Roche was not named in the Asic legal claim, but has faced strong pressure from investors to resign.
The breach follows weaker quarterly trading with revenue down against budget.
Cash and scrip deal at 48% premium is supported by Manawa shareholder Infratil.
The coffee and food retailer has plans for European expansion.
Strategic review confirms North Island site too costly for dairy and will concentrate on plant-based production.
Tower's board also approves conditional proposal to return $45m to shareholders.
Analysts upgrade stock to ‘outperform’ while highlighting growth potential for the Australian market.
The Takeovers Panel and NZ RegCo say a crucial shareholder vote on a $217.8m capital raise can go ahead as planned.